PMID- 14576364
OWN - NLM
STAT- MEDLINE
DCOM- 20040326
LR  - 20171116
IS  - 0741-5400 (Print)
IS  - 0741-5400 (Linking)
VI  - 75
IP  - 2
DP  - 2004 Feb
TI  - Autologous stem-cell transplantation restores the functional properties of 
      CD14+CD16+ monocytes in patients with myeloma and lymphoma.
PG  - 207-13
AB  - The CD14+CD16+ monocytes appear to be important to immune defense against 
      infection, as these cells are very potent with respect to tumor necrosis factor 
      (TNF) production, phagocytosis, and antigen presentation. Myeloablative high-dose 
      chemotherapy (HDT) and subsequent autologous stem-cell transplantation (ASCT) are 
      being used increasingly for therapy of hematological malignancies, but the 
      pronounced immunosuppression renders the patients prone to infection. To 
      determine the functional properties of CD14+CD16+ monocytes under these 
      conditions, 15 patients with lymphoma or myeloma were examined. Before HDT, the 
      ratio of CD14+CD16+ cells to the population of the classical CD14++ monocytes was 
      0.28 +/- 0.12; this ratio changed during the course of HDT and ASCT in favor of 
      the CD14+CD16+ monocytes to a maximum of 12.4 +/- 7.8 (P<0.001) on day 3.5 +/- 
      1.6 after transplanation (Tx) and returned to 0.11 +/- 0.07 (P<0.001) after 
      engraftment on day 11.3 +/- 2.2. Although the absolute number of classical CD14++ 
      monocytes declined to less than 1/microl at the nadir, the number of 
      CD14+CD16+monocytes fell from 29.7 +/- 9.8/microl to 4.5 +/- 3.0/microl at the 
      nadir and increased to 13.8 +/- 9.8/microl at the day of discharge from the 
      hospital. Flow cytometric analysis of phagocytosis of fluorescein isothiocyanate 
      (FITC)-labeled Escherichia coli showed that 30 +/- 10% CD14+CD16+ monocytes of 
      patients were FITC-positive before Tx, and at engrafment, the percentage of 
      FITC-positive cells had doubled to 60 +/- 6% (healthy controls, 41+/-7%). When 
      determining generation of reactive oxygen species after E. coli ingestion, the 
      CD14+CD16+ monocytes showed a decreased response before Tx (32+/-12% positve 
      cells), which increased to 53 +/- 24% after ASCT. The median fluorescence 
      intensity of human leukocyte antigen (HLA)-DR expression on the CD14+CD16+ 
      monocytes increased from 11 +/- 6 before Tx to 17 +/- 11 after Tx, and the 
      production of TNF after lipopolysaccharide showed no remarkable difference 
      (46+/-13 vs. 49+/-14 channels). At the same time, expression of TNF and of HLA-DR 
      showed a dramatic decrease in the CD14++ monocytes. Taken together after 
      stem-cell Tx, the function of the CD14++ monocytes is impaired, and the 
      functional properties of CD14+CD16+ monocytes recover, indicating that these 
      cells may be important for defense against infections post-ASCT.
FAU - Dayyani, Farshid
AU  - Dayyani F
AD  - Department of Hematology and Oncology, Medical Clinic Campus Innenstadt, 
      University of Munich, Ziemmssenstrasse 1, 80336 Munich, Germany. dayyani@web.de
FAU - Joeinig, Anke
AU  - Joeinig A
FAU - Ziegler-Heitbrock, Loms
AU  - Ziegler-Heitbrock L
FAU - Schmidmaier, Ralf
AU  - Schmidmaier R
FAU - Straka, Christian
AU  - Straka C
FAU - Emmerich, Bertold
AU  - Emmerich B
FAU - Meinhardt, Gerold
AU  - Meinhardt G
LA  - eng
PT  - Journal Article
DEP - 20031023
PL  - England
TA  - J Leukoc Biol
JT  - Journal of leukocyte biology
JID - 8405628
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Lipopolysaccharide Receptors)
RN  - 0 (Receptors, IgG)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - HLA-DR Antigens
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Lipopolysaccharide Receptors
MH  - Lymphoma/*therapy
MH  - Male
MH  - Middle Aged
MH  - Monocytes/immunology/*physiology
MH  - Multiple Myeloma/*therapy
MH  - Phagocytosis
MH  - Receptors, IgG
MH  - Respiratory Burst
MH  - Transplantation, Autologous
MH  - Tumor Necrosis Factor-alpha/biosynthesis
EDAT- 2003/10/25 05:00
MHDA- 2004/03/27 05:00
CRDT- 2003/10/25 05:00
PHST- 2003/10/25 05:00 [pubmed]
PHST- 2004/03/27 05:00 [medline]
PHST- 2003/10/25 05:00 [entrez]
AID - jlb.0803386 [pii]
AID - 10.1189/jlb.0803386 [doi]
PST - ppublish
SO  - J Leukoc Biol. 2004 Feb;75(2):207-13. doi: 10.1189/jlb.0803386. Epub 2003 Oct 23.